Impact of different age ranges on the benefits and harms of the breast cancer screening programme by the EU-TOPIA tool

M Pinto-Carbo, M Vanaclocha-Espi*, J Martin-Pozuelo, P Romeo-Cervera, M Hernandez-Garcia, J Ibanez, S Castan-Cameo, D Salas, NT van Ravesteyn, H de Koning, O Zurriaga, A Molina-Barcelo

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Downloads (Pure)

Abstract

Background
The recommendation for the implementation of mammography screening in women aged 45–49 and 70–74 is conditional with moderate certainty of the evidence. The aim of this study is to simulate the long-term outcomes (2020–50) of using different age range scenarios in the breast cancer screening programme of the Valencia Region (Spain), considering different programme participation rates.

Methods
Three age range scenarios (S) were simulated with the EU-TOPIA tool, considering a biennial screening interval: S1, 45–69 years old (y); S2, 50–69 y and S3, 45–74 y. Simulations were performed for four participation rates: A = current participation (72.7%), B = +5%, C = +10% and D = +20%. Considered benefits: number (N°) of in situ and invasive breast cancers (BC) (screen vs. clinically detected), N° of BC deaths and % BC mortality reduction. Considered harms: N° of false positives (FP) and % overdiagnosis.

Results
The results showed that BC mortality decreased in all scenarios, being higher in S3A (32.2%) than S1A (30.6%) and S2A (27.9%). Harms decreased in S2A vs. S1A (N° FP: 236 vs. 423, overdiagnosis: 4.9% vs. 5.0%) but also benefits (BC mortality reduction: 27.9% vs. 30.6%, N° screen-detected invasive BC 15/28 vs. 18/25). In S3A vs. S1A, an increase in benefits was observed (BC mortality reduction: 32.2% vs. 30.6%), N° screen-detected in situ B: 5/2 vs. 4/3), but also in harms (N° FP: 460 vs. 423, overdiagnosis: 5.8% vs. 5.0%). Similar trends were observed with increased participation.

Conclusions
As the age range increases, so does not only the reduction in BC mortality, but also the probability of FP and overdiagnosis.
Original languageEnglish
Article numberckae068
Number of pages6
JournalEuropean Journal of Public Health
DOIs
Publication statusE-pub ahead of print - 5 Apr 2024

Bibliographical note

© The Author(s) 2024. Published by Oxford University Press on behalf of the European Public Health Association

Fingerprint

Dive into the research topics of 'Impact of different age ranges on the benefits and harms of the breast cancer screening programme by the EU-TOPIA tool'. Together they form a unique fingerprint.

Cite this